ANVS stock news
This page provides real-time market news, earnings updates, and company announcements related to Annovis Bio, Inc. (ANVS).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-11 01:14 EST
Annovis Bio, Inc. (ANVS) recently announced that its independent Data Safety Monitoring Board (DSMB) has officially approved the company to proceed with the pivotal Phase III clinical trial of Buntanetap for the treatment of Alzheimer's disease.
老虎证券2026-02-12 13:08:44
Annovis Announces Two Presentations at the AD/PD 2026 International Conference
Finviz2026-03-03 13:03:53
Annovis Announces Two Presentations at the AD/PD 2026 International Conference
Finviz2026-03-03 13:03:53
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
Finviz2026-03-16 11:33:05
Annovis Bio announced that, according to the latest financial assessment, its cash and cash equivalents are expected to be sufficient to maintain normal operations until the third quarter of 2026.
老虎证券2026-03-16 11:44:59
Biopharmaceutical company Annovis Bio Inc announced that its CEO Maria Maccecchini will temporarily serve as CFO until the company finds a permanent replacement.
老虎证券2026-03-25 21:39:51
Annovis Publishes Historical Review of Buntanetap in The Scientist
Finviz2026-03-31 12:03:48
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Finviz2026-04-02 11:33:09
ANVS Consolidates After Pre-Market Rally Lacks Volume Confirmation
101 finance2026-04-06 09:09:54
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Finviz2026-04-10 12:33:49
Annovis Bio announced that, according to the latest financial assessment, its cash and cash equivalents are expected to be sufficient to maintain normal operations until the third quarter of 2026.
老虎证券2026-03-16 11:44:59
Biopharmaceutical company Annovis Bio Inc announced that its CEO Maria Maccecchini will temporarily serve as CFO until the company finds a permanent replacement.
老虎证券2026-03-25 21:39:51
Annovis Publishes Historical Review of Buntanetap in The Scientist
Finviz2026-03-31 12:03:48
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
Finviz2026-04-02 11:33:09
ANVS Consolidates After Pre-Market Rally Lacks Volume Confirmation
101 finance2026-04-06 09:09:54
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
Finviz2026-04-10 12:33:49
ANVS stock chart
ANVS stock detailsANVS stock price change
On the last trading day, ANVS stock closed at 1.57 USD, with a price change of -3.09% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more